Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells.

Unni AM, Harbourne B, Oh MH, Wild S, Ferrarone JR, Lockwood WW, Varmus H.

Elife. 2018 Nov 26;7. pii: e33718. doi: 10.7554/eLife.33718. [Epub ahead of print]

2.

Activation of KRAS mediates resistance to targeted therapy in MET exon 14 mutant non-small cell lung cancer.

Suzawa K, Offin M, Lu D, Kurzatkowski C, Vojnic M, Smith RS, Sabari JK, Tai H, Mattar M, Khodos I, de Stanchina E, Rudin CM, Kris MG, Arcila ME, Lockwood WW, Drilon A, Ladanyi M, Somwar R.

Clin Cancer Res. 2018 Oct 23. pii: clincanres.1640.2018. doi: 10.1158/1078-0432.CCR-18-1640. [Epub ahead of print]

PMID:
30352902
3.

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.

Drilon A, Somwar R, Mangatt BP, Edgren H, Desmeules P, Ruusulehto A, Smith RS, Delasos L, Vojnic M, Plodkowski AJ, Sabari J, Ng K, Montecalvo J, Chang J, Tai H, Lockwood WW, Martinez V, Riely GJ, Rudin CM, Kris MG, Arcila ME, Matheny C, Benayed R, Rekhtman N, Ladanyi M, Ganji G.

Cancer Discov. 2018 Jun;8(6):686-695. doi: 10.1158/2159-8290.CD-17-1004. Epub 2018 Apr 2.

PMID:
29610121
4.

In Vivo Validation of PAPSS1 (3'-phosphoadenosine 5'-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target.

Leung AWY, Veinotte CJ, Melong N, Oh MH, Chen K, Enfield KSS, Backstrom I, Warburton C, Yapp D, Berman JN, Bally MB, Lockwood WW.

Clin Cancer Res. 2017 Nov 1;23(21):6555-6566. doi: 10.1158/1078-0432.CCR-17-0700. Epub 2017 Aug 8.

5.

RASSF1A methylation, YAP1 activation and metastasis: a new role for an old foe in lung cancer.

Oh MH, Lockwood WW.

J Thorac Dis. 2017 May;9(5):1165-1167. doi: 10.21037/jtd.2017.04.16. No abstract available.

6.

MIR155 Regulation of Ubiquilin1 and Ubiquilin2: Implications in Cellular Protection and Tumorigenesis.

Yadav S, Singh N, Shah PP, Rowbotham DA, Malik D, Srivastav A, Shankar J, Lam WL, Lockwood WW, Beverly LJ.

Neoplasia. 2017 Apr;19(4):321-332. doi: 10.1016/j.neo.2017.02.001. Epub 2017 Mar 16.

7.

How Cancer Genomics Drives Cancer Biology: Does Synthetic Lethality Explain Mutually Exclusive Oncogenic Mutations?

Varmus H, Unni AM, Lockwood WW.

Cold Spring Harb Symp Quant Biol. 2016;81:247-255. doi: 10.1101/sqb.2016.81.030866. Epub 2017 Jan 25. Review.

PMID:
28123049
8.

Expression of the lncRNA Maternally Expressed Gene 3 (MEG3) Contributes to the Control of Lung Cancer Cell Proliferation by the Rb Pathway.

Kruer TL, Dougherty SM, Reynolds L, Long E, de Silva T, Lockwood WW, Clem BF.

PLoS One. 2016 Nov 10;11(11):e0166363. doi: 10.1371/journal.pone.0166363. eCollection 2016.

9.

Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis.

Marshall EA, Ng KW, Kung SH, Conway EM, Martinez VD, Halvorsen EC, Rowbotham DA, Vucic EA, Plumb AW, Becker-Santos DD, Enfield KS, Kennett JY, Bennewith KL, Lockwood WW, Lam S, English JC, Abraham N, Lam WL.

Mol Cancer. 2016 Oct 27;15(1):67. Review.

10.

Synthetic lethality in lung cancer and translation to clinical therapies.

Leung AW, de Silva T, Bally MB, Lockwood WW.

Mol Cancer. 2016 Sep 29;15(1):61. Review.

11.

Developmental transcription factor NFIB is a putative target of oncofetal miRNAs and is associated with tumour aggressiveness in lung adenocarcinoma.

Becker-Santos DD, Thu KL, English JC, Pikor LA, Martinez VD, Zhang M, Vucic EA, Luk MT, Carraro A, Korbelik J, Piga D, Lhomme NM, Tsay MJ, Yee J, MacAulay CE, Lam S, Lockwood WW, Robinson WP, Jurisica I, Lam WL.

J Pathol. 2016 Oct;240(2):161-72. doi: 10.1002/path.4765. Epub 2016 Sep 19.

PMID:
27357447
12.

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.

Unni AM, Lockwood WW, Zejnullahu K, Lee-Lin SQ, Varmus H.

Elife. 2015 Jun 5;4:e06907. doi: 10.7554/eLife.06907.

13.

Loss of the Notch effector RBPJ promotes tumorigenesis.

Kulic I, Robertson G, Chang L, Baker JH, Lockwood WW, Mok W, Fuller M, Fournier M, Wong N, Chou V, Robinson MD, Chun HJ, Gilks B, Kempkes B, Thomson TA, Hirst M, Minchinton AI, Lam WL, Jones S, Marra M, Karsan A.

J Exp Med. 2015 Jan 12;212(1):37-52. doi: 10.1084/jem.20121192. Epub 2014 Dec 15.

14.

Coiled-coil domain containing 68 (CCDC68) demonstrates a tumor-suppressive role in pancreatic ductal adenocarcinoma.

Radulovich N, Leung L, Ibrahimov E, Navab R, Sakashita S, Zhu CQ, Kaufman E, Lockwood WW, Thu KL, Fedyshyn Y, Moffat J, Lam WL, Tsao MS.

Oncogene. 2015 Aug 6;34(32):4238-47. doi: 10.1038/onc.2014.357. Epub 2014 Nov 10.

15.

The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.

Saurabh K, Scherzer MT, Shah PP, Mims AS, Lockwood WW, Kraft AS, Beverly LJ.

Oncotarget. 2014 Sep 30;5(18):8503-14.

16.

Ubiquilin1 represses migration and epithelial-to-mesenchymal transition of human non-small cell lung cancer cells.

Shah PP, Lockwood WW, Saurabh K, Kurlawala Z, Shannon SP, Waigel S, Zacharias W, Beverly LJ.

Oncogene. 2015 Mar 26;34(13):1709-17. doi: 10.1038/onc.2014.97. Epub 2014 Apr 21.

17.

YEATS4 is a novel oncogene amplified in non-small cell lung cancer that regulates the p53 pathway.

Pikor LA, Lockwood WW, Thu KL, Vucic EA, Chari R, Gazdar AF, Lam S, Lam WL.

Cancer Res. 2013 Dec 15;73(24):7301-12. doi: 10.1158/0008-5472.CAN-13-1897. Epub 2013 Oct 29.

18.

EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk.

Wilson IM, Vucic EA, Enfield KS, Thu KL, Zhang YA, Chari R, Lockwood WW, Radulovich N, Starczynowski DT, Banáth JP, Zhang M, Pusic A, Fuller M, Lonergan KM, Rowbotham D, Yee J, English JC, Buys TP, Selamat SA, Laird-Offringa IA, Liu P, Anderson M, You M, Tsao MS, Brown CJ, Bennewith KL, MacAulay CE, Karsan A, Gazdar AF, Lam S, Lam WL.

Oncogene. 2014 Sep 4;33(36):4464-73. doi: 10.1038/onc.2013.396. Epub 2013 Oct 7.

19.

The novel ubiquitin ligase complex, SCF(Fbxw4), interacts with the COP9 signalosome in an F-box dependent manner, is mutated, lost and under-expressed in human cancers.

Lockwood WW, Chandel SK, Stewart GL, Erdjument-Bromage H, Beverly LJ.

PLoS One. 2013 May 2;8(5):e63610. doi: 10.1371/journal.pone.0063610. Print 2013.

20.

SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/β-catenin signaling.

Thu KL, Radulovich N, Becker-Santos DD, Pikor LA, Pusic A, Lockwood WW, Lam WL, Tsao MS.

Oncogene. 2014 Jan 16;33(3):279-88. doi: 10.1038/onc.2012.595. Epub 2013 Jan 14.

PMID:
23318427
21.

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.

Lockwood WW, Zejnullahu K, Bradner JE, Varmus H.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19408-13. doi: 10.1073/pnas.1216363109. Epub 2012 Nov 5.

22.

The hedgehog processing pathway is required for NSCLC growth and survival.

Rodriguez-Blanco J, Schilling NS, Tokhunts R, Giambelli C, Long J, Liang Fei D, Singh S, Black KE, Wang Z, Galimberti F, Bejarano PA, Elliot S, Glassberg MK, Nguyen DM, Lockwood WW, Lam WL, Dmitrovsky E, Capobianco AJ, Robbins DJ.

Oncogene. 2013 May 2;32(18):2335-45. doi: 10.1038/onc.2012.243. Epub 2012 Jun 25.

23.

Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development.

Lockwood WW, Wilson IM, Coe BP, Chari R, Pikor LA, Thu KL, Solis LM, Nunez MI, Behrens C, Yee J, English J, Murray N, Tsao MS, Minna JD, Gazdar AF, Wistuba II, MacAulay CE, Lam S, Lam WL.

PLoS One. 2012;7(5):e37775. doi: 10.1371/journal.pone.0037775. Epub 2012 May 21.

24.

Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability.

Thu KL, Vucic EA, Chari R, Zhang W, Lockwood WW, English JC, Fu R, Wang P, Feng Z, MacAulay CE, Gazdar AF, Lam S, Lam WL.

PLoS One. 2012;7(3):e33003. doi: 10.1371/journal.pone.0033003. Epub 2012 Mar 7.

25.

Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma.

Lin L, Bass AJ, Lockwood WW, Wang Z, Silvers AL, Thomas DG, Chang AC, Lin J, Orringer MB, Li W, Glover TW, Giordano TJ, Lam WL, Meyerson M, Beer DG.

Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4251-6. doi: 10.1073/pnas.1011989109. Epub 2012 Feb 28.

26.

Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma.

Lockwood WW, Thu KL, Lin L, Pikor LA, Chari R, Lam WL, Beer DG.

Clin Cancer Res. 2012 Apr 1;18(7):1936-46. doi: 10.1158/1078-0432.CCR-11-1431. Epub 2012 Feb 10.

27.

Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1.

Beverly LJ, Lockwood WW, Shah PP, Erdjument-Bromage H, Varmus H.

Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):E119-26. doi: 10.1073/pnas.1119167109. Epub 2012 Jan 10.

28.

Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines.

Somwar R, Erdjument-Bromage H, Larsson E, Shum D, Lockwood WW, Yang G, Sander C, Ouerfelli O, Tempst PJ, Djaballah H, Varmus HE.

Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16375-80. doi: 10.1073/pnas.1113554108. Epub 2011 Sep 19.

29.

TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer.

Starczynowski DT, Lockwood WW, Deléhouzée S, Chari R, Wegrzyn J, Fuller M, Tsao MS, Lam S, Gazdar AF, Lam WL, Karsan A.

J Clin Invest. 2011 Oct;121(10):4095-105. doi: 10.1172/JCI58818. Epub 2011 Sep 12.

30.

Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.

Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faça VM, Kelly-Spratt K, Wong CH, Zhang Q, Chin A, Park KS, Goodman G, Gazdar AF, Sage J, Dinulescu DM, Kucherlapati R, Depinho RA, Kemp CJ, Varmus HE, Hanash SM.

Cancer Cell. 2011 Sep 13;20(3):289-99. doi: 10.1016/j.ccr.2011.08.007.

31.

miR-101 DNA copy loss is a prominent subtype specific event in lung cancer.

Thu KL, Chari R, Lockwood WW, Lam S, Lam WL.

J Thorac Oncol. 2011 Sep;6(9):1594-8. doi: 10.1097/JTO.0b013e3182217d81.

32.

Genetic disruption of KEAP1/CUL3 E3 ubiquitin ligase complex components is a key mechanism of NF-kappaB pathway activation in lung cancer.

Thu KL, Pikor LA, Chari R, Wilson IM, Macaulay CE, English JC, Tsao MS, Gazdar AF, Lam S, Lam WL, Lockwood WW.

J Thorac Oncol. 2011 Sep;6(9):1521-9. doi: 10.1097/JTO.0b013e3182289479.

33.

Cyclin E1 is amplified and overexpressed in osteosarcoma.

Lockwood WW, Stack D, Morris T, Grehan D, O'Keane C, Stewart GL, Cumiskey J, Lam WL, Squire JA, Thomas DM, O'Sullivan MJ.

J Mol Diagn. 2011 May;13(3):289-96. doi: 10.1016/j.jmoldx.2010.11.020. Epub 2011 Mar 31.

34.

Lung cancer cell lines as tools for biomedical discovery and research.

Gazdar AF, Girard L, Lockwood WW, Lam WL, Minna JD.

J Natl Cancer Inst. 2010 Sep 8;102(17):1310-21. doi: 10.1093/jnci/djq279. Epub 2010 Aug 2. Review.

35.

Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma.

Lockwood WW, Chari R, Coe BP, Thu KL, Garnis C, Malloff CA, Campbell J, Williams AC, Hwang D, Zhu CQ, Buys TP, Yee J, English JC, Macaulay C, Tsao MS, Gazdar AF, Minna JD, Lam S, Lam WL.

PLoS Med. 2010 Jul 27;7(7):e1000315. doi: 10.1371/journal.pmed.1000315.

36.

An integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer.

Chari R, Coe BP, Vucic EA, Lockwood WW, Lam WL.

BMC Syst Biol. 2010 May 17;4:67. doi: 10.1186/1752-0509-4-67.

37.

Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer.

Chari R, Thu KL, Wilson IM, Lockwood WW, Lonergan KM, Coe BP, Malloff CA, Gazdar AF, Lam S, Garnis C, MacAulay CE, Alvarez CE, Lam WL.

Cancer Metastasis Rev. 2010 Mar;29(1):73-93. doi: 10.1007/s10555-010-9199-2. Review.

38.

Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.

Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, Varella-Garcia M, Vooder T, Wistuba II, Lam S, Brekken R, Toyooka S, Minna JD, Lam WL, Gazdar AF.

PLoS One. 2009 Oct 14;4(10):e7464. doi: 10.1371/journal.pone.0007464.

39.

Comparative genomic hybridization on BAC arrays.

Coe BP, Lockwood WW, Chari R, Lam WL.

Methods Mol Biol. 2009;556:7-19. doi: 10.1007/978-1-60327-192-9_2.

PMID:
19488868
40.

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.

Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W, Yamamoto H, Peyton M, Girard L, Lockwood WW, Lam WL, Varella-Garcia M, Minna JD, Gazdar AF.

PLoS One. 2009;4(2):e4576. doi: 10.1371/journal.pone.0004576. Epub 2009 Feb 24.

41.

MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors.

Kubo T, Yamamoto H, Lockwood WW, Valencia I, Soh J, Peyton M, Jida M, Otani H, Fujii T, Ouchida M, Takigawa N, Kiura K, Shimizu K, Date H, Minna JD, Varella-Garcia M, Lam WL, Gazdar AF, Toyooka S.

Int J Cancer. 2009 Apr 15;124(8):1778-84. doi: 10.1002/ijc.24150. Erratum in: Int J Cancer. 2015 Jan 15;136(2):E1.

42.

Integrative genomic and gene expression analysis of chromosome 7 identified novel oncogene loci in non-small cell lung cancer.

Campbell JM, Lockwood WW, Buys TP, Chari R, Coe BP, Lam S, Lam WL.

Genome. 2008 Dec;51(12):1032-9. doi: 10.1139/G08-086.

PMID:
19088816
43.

PIK3CA mutations and copy number gains in human lung cancers.

Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, Soh J, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Date H, Lam WL, Minna JD, Gazdar AF.

Cancer Res. 2008 Sep 1;68(17):6913-21. doi: 10.1158/0008-5472.CAN-07-5084.

44.

Evolving strategies for global gene expression analysis of cancer.

Coe BP, Chari R, Lockwood WW, Lam WL.

J Cell Physiol. 2008 Dec;217(3):590-7. doi: 10.1002/jcp.21554. Review.

PMID:
18680120
45.

Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells.

Gao K, Lockwood WW, Li J, Lam W, Li G.

Int J Oncol. 2008 Jun;32(6):1343-9.

PMID:
18497997
46.

DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers.

Lockwood WW, Chari R, Coe BP, Girard L, Macaulay C, Lam S, Gazdar AF, Minna JD, Lam WL.

Oncogene. 2008 Jul 31;27(33):4615-24. doi: 10.1038/onc.2008.98. Epub 2008 Apr 7.

47.

Computational methods for the analysis of array comparative genomic hybridization.

Chari R, Lockwood WW, Lam WL.

Cancer Inform. 2007 Feb 10;2:48-58.

48.

SIGMA: a system for integrative genomic microarray analysis of cancer genomes.

Chari R, Lockwood WW, Coe BP, Chu A, Macey D, Thomson A, Davies JJ, MacAulay C, Lam WL.

BMC Genomics. 2006 Dec 27;7:324.

49.

Whole genome tiling path array CGH analysis of segmental copy number alterations in cervical cancer cell lines.

Lockwood WW, Coe BP, Williams AC, MacAulay C, Lam WL.

Int J Cancer. 2007 Jan 15;120(2):436-43.

50.

Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer.

Coe BP, Lockwood WW, Girard L, Chari R, Macaulay C, Lam S, Gazdar AF, Minna JD, Lam WL.

Br J Cancer. 2006 Jun 19;94(12):1927-35. Epub 2006 May 16.

Supplemental Content

Loading ...
Support Center